Topical Hemostat Market by Product, Formulation, Application, End-Use

List of Tables

[184 Pages Report] The Topical Hemostat Market size was estimated at USD 2.12 billion in 2023 and expected to reach USD 2.26 billion in 2024, at a CAGR 6.80% to reach USD 3.36 billion by 2030.

A topical hemostat refers to products used to promote hemostasis, a process of stopping bleeding. It is applied directly to a wound or surgical site to prevent excessive blood loss and to encourage clot formation. Topical hemostats are used in various medical situations, from emergency settings and surgical procedures to managing chronic wounds. Topical hemostats contain active substances that accelerate the body's natural clotting process or provide a physical barrier to assist with blood containment. A global rise in surgeries due to an aging population and the elevating incidences of chronic diseases is driving the market. However, the high cost of advanced hemostats and potential complications associated with using certain hemostatic agents can restrict their application and limit their accessibility. Nevertheless, the development of synthetic and bioactive materials that can mimic natural hemostasis and the utilization of nanotechnology in developing advanced hemostatic agents are expected to create lucrative opportunities for the topical hemostat market.

KEY MARKET STATISTICS
Base Year [2023]	USD 2.12 billion
Estimated Year [2024]	USD 2.26 billion
Forecast Year [2030]	USD 3.36 billion
CAGR (%)	6.80%

Product: Burgeoning adoption of combination topical hemostats owing to the additional benefits such as infection reduction

Collagen-based topical hemostats are derived from animal collagen, which promotes hemostasis by providing a matrix that facilitates clot formation. Collagen attracts and activates platelets, enhancing the natural coagulation cascade. These products, such as sponges, powders, or films, can come in various forms and are used in different surgical scenarios to control bleeding. Combination topical hemostats incorporate multiple hemostatic agents or mechanisms to enhance their efficacy. They often combine a physical matrix, such as collagen or gelatin, with a procoagulant substance like thrombin or an antibiotic agent to prevent infection. These multi-action products provide simultaneous bleeding control and additional benefits such as infection reduction and are suitable for use in more challenging bleeding situations in surgical settings. Gelatin-based topical hemostats consist of porcine or bovine-derived gelatin and often come as granules, foams, or compressed sponges. These hemostats provide a physical matrix that can absorb blood and concentrate clotting factors at the bleeding site. Gelatin-based hemostats are commonly used in surgical and emergency settings due to their efficacy and ease of application. Oxidized regenerated cellulose-based topical hemostats are made from plant-derived cellulose that is chemically treated to improve its hemostatic properties. These products provide a matrix for clotting and lowering the pH around the wound, which assists in the hemostasis process. Thrombin-based topical hemostats contain thrombin, an enzyme that converts fibrinogen to fibrin, thereby inducing clot formation. These hemostats can be made from human, bovine, or recombinant thrombin and are often applied in conjunction with other materials, including gelatin or collagen pads. This category of hemostatic agent is particularly useful in controlling bleeding when the application of manual pressure is insufficient or impractical.

Formulation: Proliferating utilization of matrix and gel hemostats owing to their ability to conform to irregular wound surfaces

Matrix and gel hemostats are bioresorbable agents that work on the principle of providing a physical scaffold to assist in the formation of a stable blood clot. They often contain natural or synthetic substances such as collagen, gelatin, or cellulose. These materials can be combined with thrombin or other active clotting agents to enhance hemostasis. Powder hemostats comprise granular or fluffy materials that adhere to the wound site and assist in clotting through dehydration mechanisms and concentration of clotting factors. Active ingredients such as kaolin, zeolite, or other mineral substances are commonly used. They are particularly advantageous for their ease of application on bleeding surfaces, their usefulness in minimally invasive procedures, and their ability to be applied using applicators or insufflators. Sheet and pad hemostats are usually flat configurations of hemostatic materials designed to be placed directly onto bleeding tissue surfaces. Materials such as oxidized regenerated cellulose (ORC), polyethylene glycol (PEG) polymers, and collagen are commonly used in these formats. They are often preferred for their ease of handling, ability to cut to required shapes, and suitability for providing a mechanical barrier that facilitates clot formation. Sponge hemostats are made from absorbable materials such as gelatin or collagen, which have a porous structure that provides mechanical support for clot formation and a matrix for platelet adhesion and aggregation. These hemostats are commonly used in various surgical procedures and can be applied to oozing surfaces or fill cavities where controlling bleeding is challenging.

Application: Significant usage of topical hemostats in cardiovascular surgery

In cardiovascular surgery, topical hemostats are extensively used to manage bleeding from vascular anastomoses, graft sites, and heart tissues. They are pivotal in promoting hemostasis in high-risk patients or scenarios where precise hemostatic control is critical to prevent excessive blood loss and potential complications such as hematoma formation or reoperation due to bleeding. General surgery involves various procedures where topical hemostats are applied to control bleeding from the surgical site. Whether in open or laparoscopic procedures, these agents reduce intraoperative bleeding. They can be used on various tissues and organs to ensure a drier operative field, which may improve surgical outcomes and shorten operative times. Liver and spleen lacerations often result in significant bleeding due to the vascular nature of these organs. Topical hemostats are crucial in managing bleeding in such cases, providing rapid hemostasis for patient stability. Orthopedic surgeries, particularly those involving joint replacements or bone cutting, can cause significant bleeding. Topical hemostats are used to provide hemostasis at bone surfaces and soft tissue, reducing intraoperative bleeding and potentially minimizing postoperative bruising, hematoma, and improving healing time. In reconstructive surgery, achieving meticulous hemostasis is critical to ensure graft viability and aesthetic outcomes. Topical hemostats are utilized to manage bleeding from both donor and recipient sites, minimizing blood loss and mitigating the risk of postoperative complications such as seroma or hematoma formation, which could compromise the success of the reconstruction.

End-Use: Evolving utilization of topical hemostats in hospitals

Topical hemostats are utilized across various departments of hospitals, such as emergency wards and operating theatres, especially in surgeries involving high bleeding risks, such as cardiovascular, orthopedic, and organ transplantations. Hospitals often require a consistent supply of hemostats due to their broad service in complex and routine surgeries, making them a critical market for manufacturers. Nursing homes adopt topical hemostats, focusing mainly on the geriatric population that may require minor surgical or invasive procedures. Although the volume of use in nursing homes is significantly lower than in hospitals, they still need an array of hemostatic agents to cater to patients who may have heightened bleeding risks due to age-related comorbid conditions. Ambulatory surgical centers, or outpatient surgical centers, are specialized facilities where surgeries that do not require hospital admission. These centers value efficiency and the rapid turnover of surgical cases, often looking for fast-acting topical hemostats to enhance patient throughput and reduce procedure times. The frequency of elective surgeries, such as cosmetic and minimally invasive procedures, at these centers contributes to a steady demand for hemostatic products.

Regional Insights

The Americas exhibit robust growth in the topical hemostat market supported by healthcare infrastructure, high per capita healthcare expenditure, and a focus on advanced surgical procedures. Furthermore, the consumer need, due to the prevalence of surgical procedures and advanced wound management practices with high awareness of the effectiveness of topical hemostats and the readiness of healthcare providers to adopt new technologies, bolster the market growth. Recent investments are primarily channeled toward developing advanced biocompatible and biodegradable hemostats in the Americas. The European Union boasts a sophisticated healthcare system with a strong emphasis on patient safety and high standards of care, which drives the demand for topical hemostats in Europe. The presence of major pharmaceutical companies, coupled with significant investments in research, creates a favorable environment for market growth. On the other hand, in the Middle East and Africa, the market is growing owing to consumers' awareness of advanced medical products and rising demand linked to the development of healthcare infrastructure and the private healthcare sector. Investments and initiatives in these regions focus on capacity building in healthcare services, including adopting effective surgical aids such as topical hemostats. The Asia Pacific region presents a diverse and rapidly expanding topical hemostat market owing to its sizeable populations, growing economies, and investment in healthcare innovation. Furthermore, government backing and a focus on self-sufficiency in healthcare technologies have spurred market growth, leading to a surge in local manufacturing and innovation. The latest patents in the APAC region reflect a drive towards developing innovative hemostatic agents suitable for the local market, considering the economic and healthcare delivery constraints.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Topical Hemostat Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Topical Hemostat Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Topical Hemostat Market, highlighting leading vendors and their innovative profiles. These include Aegis Lifesciences Private Limited, Axio Biosolutions Pvt Ltd, B.Braun Melsungen AG, Baxter International, Inc., Becton, Dickinson and Company, Betatech Medical, BioCer Entwicklungs-GmbH, Bristol-Myers Squibb Company, Dilon Technologies Inc, GELITA MEDICAL GmbH, Hemostasis, LLC, Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., Marine Polymer Technologies, Inc., Medline Industries, LP, Medtrade Products Ltd, Medtronic PLC, Meril Life Sciences Pvt. Ltd, Pfizer Inc., Southmedic Inc., Stryker Corporation, SYMATESE SAS, Takeda Pharmaceutical Company Limited, Teleflex Incorporated, and Zeria Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Topical Hemostat Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Collagen-Based Topical Hemostats
- Combination Topical Hemostats
- Gelatin-Based Topical Hemostats
- Oxidized Regenerated Cellulose-based Topical Hemostats
- Thrombin-Based Topical Hemostats

Formulation
- Matrix & Gel Hemostats
- Powder Hemostats
- Sheet & Pad Hemostats
- Sponge Hemostats

Application
- Cardiovascular Surgery
- General Surgery
- Liver & Spleen Lacerations
- Orthopedic Surgery
- Reconstructive Surgery

End-Use
- Hospitals
- Nursing Homes
- Surgical Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Topical Hemostat Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Topical Hemostat Market?

3. What are the technology trends and regulatory frameworks in the Topical Hemostat Market?

4. What is the market share of the leading vendors in the Topical Hemostat Market?

5. Which modes and strategic moves are suitable for entering the Topical Hemostat Market?

Product Code: MRR-031AB52F47EB

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising numbers of surgeries due to an aging population and prevalence of chronic diseases
  - 5.1.1.2. Favorable product approval by medical regulators
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with topical hemostat products
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing R&D for the introduction of novel topical hemostat
  - 5.1.3.2. Integration of nanotechnology to create more efficient topical hemostats
- 5.1.4. Challenges
  - 5.1.4.1. Operational limitations and risk of infection associated with the use of topical hemostats
5.2. Market Segmentation Analysis
- 5.2.1. Product: Burgeoning adoption of combination topical hemostats owing to the additional benefits such as infection reduction
- 5.2.2. Formulation: Proliferating utilization of matrix and gel hemostats owing to their ability to conform to irregular wound surfaces
- 5.2.3. Application: Significant usage of topical hemostats in cardiovascular surgery
- 5.2.4. End-Use: Evolving utilization of topical hemostats in hospitals
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Topical Hemostat Market, by Product

6.1. Introduction
6.2. Collagen-Based Topical Hemostats
6.3. Combination Topical Hemostats
6.4. Gelatin-Based Topical Hemostats
6.5. Oxidized Regenerated Cellulose-based Topical Hemostats
6.6. Thrombin-Based Topical Hemostats

7. Topical Hemostat Market, by Formulation

7.1. Introduction
7.2. Matrix & Gel Hemostats
7.3. Powder Hemostats
7.4. Sheet & Pad Hemostats
7.5. Sponge Hemostats

8. Topical Hemostat Market, by Application

8.1. Introduction
8.2. Cardiovascular Surgery
8.3. General Surgery
8.4. Liver & Spleen Lacerations
8.5. Orthopedic Surgery
8.6. Reconstructive Surgery

9. Topical Hemostat Market, by End-Use

9.1. Introduction
9.2. Hospitals
9.3. Nursing Homes
9.4. Surgical Centers

10. Americas Topical Hemostat Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Topical Hemostat Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Topical Hemostat Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Ethicon Introduces ETHIZIA Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive Bleeding
- 13.3.2. Medcura Receives Breakthrough Device Designation for its LifeGel Absorbable Surgical Hemostat
- 13.3.3. Hemostasis Closes Acquisition of Fiagon Medical Technologies
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio